FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Tadeusz Robak

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Jolanta D Żołnierczyk; Tadeusz Robak; Piotr Smolewski; Jerzy Z Błoński; Arleta Borowiak; Barbara Cebula-Obrzut; Paweł Hikisz; Zofia M Kiliańska
Promising anti-leukemic activity of atorvastatin.
Ewa Wawrzyniak; Agnieszka Wierzbowska; Renata Woroniecka; Ewa Duszenko; Anna Ejduk; Sebastian Grosicki; Jerzy Holowiecki; Mariola Iliszko; Malgorzata Jakobczyk; Anna Jaskowiec; Agnieszka Klonowska; Wanda Knopinska-Posluszny; Joanna Kosny; Aleksandra Kotkowska; Barbara Mucha; Barbara Pienkowska-Grela; Agnieszka Pluta; Tadeusz Robak; Monika Siemieniuk-Rys; Malgorzata Wach; Olga Haus
Different prognosis of acute myeloid leukemia harboring monosomal karyotype with total or partial monosomies determined by FISH: retrospective PALG study.
Ewa Lech-Maranda; Miroslaw Majewski; Wojciech M Mlynarski; Agata Pastorczak; Tadeusz Robak; Maciej Borowiec; Barbara Cebula-Obrzut; Olga Grzybowska-Izydorczyk; Gabriela Klimkiewicz-Wojciechowska; Aleksandra Kotkowska; Monika Wcislo; Krzysztof Warzocha
Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Tadeusz Robak (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jolanta D Żołnierczyk; Tadeusz Robak; Piotr Smolewski; Jerzy Z Błoński; Arleta Borowiak; Barbara Cebula-Obrzut; Paweł Hikisz; Zofia M Kiliańska
Promising anti-leukemic activity of atorvastatin.
Oncology reports 2013;29(5):2065-71.
2013: Ewa Wawrzyniak; Agnieszka Wierzbowska; Renata Woroniecka; Ewa Duszenko; Anna Ejduk; Sebastian Grosicki; Jerzy Holowiecki; Mariola Iliszko; Malgorzata Jakobczyk; Anna Jaskowiec; Agnieszka Klonowska; Wanda Knopinska-Posluszny; Joanna Kosny; Aleksandra Kotkowska; Barbara Mucha; Barbara Pienkowska-Grela; Agnieszka Pluta; Tadeusz Robak; Monika Siemieniuk-Rys; Malgorzata Wach; Olga Haus
Different prognosis of acute myeloid leukemia harboring monosomal karyotype with total or partial monosomies determined by FISH: retrospective PALG study.
Leukemia research 2013;37(3):293-9.
2013: Ewa Lech-Maranda; Miroslaw Majewski; Wojciech M Mlynarski; Agata Pastorczak; Tadeusz Robak; Maciej Borowiec; Barbara Cebula-Obrzut; Olga Grzybowska-Izydorczyk; Gabriela Klimkiewicz-Wojciechowska; Aleksandra Kotkowska; Monika Wcislo; Krzysztof Warzocha
Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia.
Genes, chromosomes & cancer 2013;52(3):287-96.
2013: Jakub Bogusz; Barbara Cebula-Obrzut; Agata Majchrzak; Aleksandra Mędra; Tadeusz Robak; Piotr Smolewski
Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
Postȩpy higieny i medycyny doświadczalnej (Online) 2013;67():107-18.
2013: J Treliński; Tadeusz Robak
JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Current medicinal chemistry 2013;20(9):1147-61.
2013: Tadeusz Robak
Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
Future oncology (London, England) 2013;9(1):69-91.
2013: Małgorzata Rogalińska; Jerzy Z Błoński; Ida Franiak-Pietryga; Paweł Góralski; Agnieszka Janus; Henryk Maciejewski; Marek Mirowski; Henryk Piekarski; Tadeusz Robak; Pawel Robak; Zofia M Kiliańska
Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases.
Cancer biology & therapy 2013;14(1):6-12.
2012: Ewa Lech-Maranda; Hanna Makuch-Lasica; Wojciech Mlynarski; Grazyna Nowak; Tadeusz Robak; Karolina Antosik; Przemyslaw Bilinski; Maciej Borowiec; Barbara Cebula-Obrzut; Olga Grzybowska-Izydorczyk; Gabriela Klimkiewicz-Wojciechowska; Ewa Wawrzyniak; Krystyna Wyka; Krzysztof Warzocha
Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Archivum immunologiae et therapiae experimentalis 2012;60(6):477-86.
2012: Anna Korycka-Wołowiec; Tadeusz Robak
Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies.
Expert opinion on drug metabolism & toxicology 2012;8(11):1455-68.
2012: Ida Franiak-Pietryga; Paolo Ghia; Agnieszka Janus; Aleksandra Kotkowska; Henryk Maciejewski; Marek Mirowski; Tadeusz Robak; Aleksandra Salagacka; Ewa Wawrzyniak; Dariusz Wolowiec; Jerzy Z Blonski; Anna Korycka-Wolowiec
Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results.
Leukemia research 2012;36(9):1134-40.
2012: Jerzy Holowiecki; Wieslaw W Jedrzejczak; Marek Kielbinski; Janusz Kloczko; Mieczyslaw Komarnicki; Kazimierz Kuliczkowski; Slawomira Kyrcz-Krzemien; Beata Piatkowska-Jakubas; Tadeusz Robak; Aleksander B Skotnicki; Kazimierz Sulek; Malgorzata Wach; Krzysztof Warzocha; Agnieszka Wierzbowska; Krystyna Zawilska; Barbara Zdziarska; Anna Dmoszynska; Sebastian Giebel; Sebastian Grosicki; Andrzej Hellmann; Olga Haus
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(20):2441-8.
2012: Tadeusz Robak; Ewa Robak
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Expert opinion on investigational drugs 2012;21(7):921-47.
2012: Krzysztof Jamroziak; Dorota Jesionek-Kupnicka; Joanna Gora-Tybor; Olga Grzybowska-Izydorczyk; Tadeusz Robak
Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukemia treated with cladribine.
British journal of haematology 2012;158(2):286-8; author reply 289.
2012: Tadeusz Robak
Editorial : novel and emerging drugs for leukemias.
Current cancer drug targets 2012;12(5):453-7.
2012: A Wolska; P Kopka; Agnieszka Pluta; Tadeusz Robak; Anna Szmigielska-Kaplon; Agnieszka Wierzbowska
Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) - a single-center experience.
Advances in medical sciences 2012;57(1):118-23.
2012: Tadeusz Robak
Rituximab for chronic lymphocytic leukemia.
Expert opinion on biological therapy 2012;12(4):503-15.
2012: Ewelina Ziółkowska; Tadeusz Robak; Piotr Smolewski; Jerzy Z Błońsk; Barbara Cebula-Obrzut; Ida Franiak-Pietryga; Anna Korycka-Wołowiec
Type of serum influences the rituximab dependent cytotoxicity and apoptosis of chronic lymphocytic leukemia cells in vitro.
Postȩpy higieny i medycyny doświadczalnej (Online) 2012;66():730-8.
2012: Pawel Robak; Tadeusz Robak
A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
Current medicinal chemistry 2012;19(31):5294-318.
2012: Ida Franiak-Pietryga; Jerzy Z Błoński; Maciej Borowiec; Henryk Maciejewski; Marek Mirowski; Tadeusz Robak; Aleksandra Sałagacka; Anna Korycka-Wołowiec
Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study.
Pharmacological reports : PR 2012;64(2):412-20.
2012: Tadeusz Robak; Pawel Robak
Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias.
Current pharmaceutical design 2012;18(23):3373-88.
2012: E Robak; Tadeusz Robak
Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity.
Current medicinal chemistry 2012;19(3):438-53.
2011: Tadeusz Robak
Management of hairy cell leukemia variant.
Leukemia & lymphoma 2011;52 Suppl 2():53-6.
2011: Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
The lancet oncology 2011;12(5):431-40.
2011: Tadeusz Robak
New nucleoside analogs for patients with hematological malignancies.
Expert opinion on investigational drugs 2011;20(3):343-59.
2011: Joan Bladé; Pieter Sonneveld; Jesús F San Miguel; Heather J Sutherland; Roman Hajek; Arnon Nagler; Andrew Spencer; Tadeusz Robak; Keith C Lantz; Sen H Zhuang; Jean-Luc Harousseau; Robert Z Orlowski
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
Clinical lymphoma, myeloma & leukemia 2011;11(1):44-9.
2011: Tadeusz Robak; Ewa Robak
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2011;25(1):13-25.
2011: Tadeusz Robak
Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment.
Cancer treatment reviews 2011;37(1):3-10.
2011: Piotr Pluta; Tadeusz Robak; Piotr Smolewski; Agnieszka Wierzbowska; A Bilski; B Cebula-Obrzut; V Ehemann; R Kordek; Dariusz Nejc; J Piekarski; A Pluta; Arkadiusz Jeziorski
Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients.
Neoplasma 2011;58(5):430-5.
2011: Tadeusz Robak; A Szmigielska-Kapłon; Agnieszka Pluta; Olga Grzybowska-Izydorczyk; A Wolska; M Czemerska; Agnieszka Wierzbowska
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Current medicinal chemistry 2011;18(5):638-66.
2011: Ewa Lech-Maranda; Ewa Robak; Tadeusz Robak
Novel systemic drugs for cutaneous T-cell lymphoma.
Recent patents on anti-cancer drug discovery 2011;6(1):70-93.
2010: Tadeusz Robak; Ewa Lech-Maranda; Pawel Robak
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Expert review of anticancer therapy 2010;10(10):1529-43.
2010: Tadeusz Robak; Claudia Mainau; Barbara Pyringer; Krzysztof Chojnowski; Krzysztof Warzocha; Anna Dmoszynska; Jan Straub; Paul Imbach
Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.
Hematology (Amsterdam, Netherlands) 2010;15(5):351-9.
2010: Agnieszka Pluta; Agata Wrzesien-Kus; Barbara Cebula-Obrzut; Anna Wolska; Anna Szmigielska-Kaplon; Magdalena Czemerska; Piotr Pluta; Tadeusz Robak; Piotr Smolewski; Agnieszka Wierzbowska
Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients.
Leukemia research 2010;34(10):1308-13.
2010: Jacek Treliński; Agnieszka Wierzbowska; Anna Krawczyńska; Agata Sakowicz; Tadeusz Pietrucha; Piotr Smolewski; Tadeusz Robak; Krzysztof Chojnowski
Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.
Leukemia & lymphoma 2010;51(9):1727-33.
2010: Anna Szmigielska-Kapłon; Ewa Lech-Maranda; Dorota Jesionek-Kupnicka; Joanna Góra-Tybor; Jerzy Z Błoński; Marek Kasznicki; Radzislaw Kordek; Tadeusz Robak
Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia.
Leukemia & lymphoma 2010;51(7):1351-3.
2010: Jacek Treliński; Agnieszka Wierzbowska; Anna Krawczyńska; Agata Sakowicz; Tadeusz Pietrucha; Piotr Smolewski; Tadeusz Robak; Krzysztof Chojnowski
Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.
International journal of hematology 2010;91(5):792-8.
2010: Tadeusz Robak; Krzysztof Jamroziak; Joanna Gora-Tybor; Beata Stella-Holowiecka; Lech Konopka; Bernadetta Ceglarek; Krzysztof Warzocha; Ilona Seferynska; Jaroslaw Piszcz; Malgorzata Calbecka; Aleksandra Kostyra; Jadwiga Dwilewicz - Trojaczek; Anna Dmoszyñska; Krystyna Zawilska; Andrzej Hellmann; Andrzej Zdunczyk; Stanislaw Potoczek; Magdalena Piotrowska; Krzysztof Lewandowski; Jerzy Z Blonski
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(11):1863-9.
2010: Tadeusz Robak; Anna Dmoszynska; Philippe Solal-Céligny; Krzysztof Warzocha; Javier Loscertales; John Catalano; Boris V Afanasiev; Loree Larratt; Christian H Geisler; Marco Montillo; Ilya Zyuzgin; Peter S Ganly; Caroline Dartigeas; András Rosta; Jörg Maurer; Myriam Mendila; M Wayne Saville; Nancy Valente; Michael K Wenger; Sergey I Moiseev
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(10):1756-65.
2010: Ewa Lech-Maranda; Jacques Bienvenu; Florence Broussais-Guillaumot; Krzysztof Warzocha; Anne-Sophie Michallet; Tadeusz Robak; Bertrand Coiffier; Gilles SALLES
Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Archivum immunologiae et therapiae experimentalis 2010;58(2):131-41.
2010: Olga Grzybowska-Izydorczyk; Barbara Cebula; Tadeusz Robak; Piotr Smolewski
Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia.
European journal of cancer (Oxford, England : 1990) 2010;46(4):800-10.
2010: Ewa Lech-Maranda; Marek Seweryn; Sebastian Giebel; Jerzy Holowiecki; Beata Piatkowska-Jakubas; Joanna Wegrzyn; Aleksander Skotnicki; Marek Kielbinski; Kazimierz Kuliczkowski; Monika Paluszewska; Wieslaw Wiktor Jedrzejczak; Magdalena Dutka; Andrzej Hellmann; Marcin Flont; Barbara Zdziarska; Grazyna Palynyczko; Lech Konopka; Tomasz Szpila; Krzysztof Gawronski; Kazimierz Sulek; Jaroslaw Sokolowski; Janusz Kloczko; Krzysztof Warzocha; Tadeusz Robak
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2010;14(2):e132-40.
2010: Tadeusz Robak
Improving FCR immunochemotherapy in CLL.
Blood 2010;115(3):437-8.
2010: Tadeusz Robak
Application of new drugs in chronic lymphocytic leukemia.
Mediterranean journal of hematology and infectious diseases 2010;2(2):e2010011.
2010: Małgorzata Rogalińska; Jerzy Z Błoński; Oxana Komina; Paweł Góralski; Jolanta D Zołnierczyk; Henryk Piekarski; Tadeusz Robak; Zofia M Kiliańska; Józefa Wesierska-Gadek
R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
Journal of cellular biochemistry 2010;109(1):217-35.
2009: Tadeusz Robak; Pawel Robak; Piotr Smolewski
TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
Current opinion in investigational drugs (London, England : 2000) 2009;10(12):1383-90.
2009: Jian-Miao Liu; Joanna Gora-Tybor; Olga Grzybowska-Izydorczyk; Jerome Bignon; Tadeusz Robak; Joanna Wdzieczak-Bakala
Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies.
Leukemia & lymphoma 2009;50(12):2096-7.
2009: Jacek Treliński; Marzena Tybura; Piotr Smolewski; Tadeusz Robak; Krzysztof Chojnowski
The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2009;20(8):646-51.
2009: Michal Plewka; Maria Krzemińska-Pakuła; Piotr Lipiec; Jan Z Peruga; Tomasz Jezewski; Michal Kidawa; Karina Wierzbowska-Drabik; Anna Korycka; Tadeusz Robak; Jaroslaw D Kasprzak
Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction.
The American journal of cardiology 2009;104(10):1336-42.
2009: Agnieszka Janus; Anna Linke; Barbara Cebula; Tadeusz Robak; Piotr Smolewski
Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
Anti-cancer drugs 2009;20(8):693-701.
2009: Jolanta D Zolnierczyk; Jerzy Z Błoński; Tadeusz Robak; Zofia M Kiliańska; Józefa Wesierska-Gadek
Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Annals of the New York Academy of Sciences 2009;1171():124-31.
2009: Tadeusz Robak; A Salama; L Kovaleva; Y Vyhovska; S V Davies; M G Mazzucconi; O Zenker; P Kiessling
Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura.
Hematology (Amsterdam, Netherlands) 2009;14(4):227-36.
2009: Ewa Lech-Maranda; Anna Korycka; Tadeusz Robak
Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
Mini reviews in medicinal chemistry 2009;9(7):805-12.
2009: Tadeusz Robak
GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Current opinion in investigational drugs (London, England : 2000) 2009;10(6):588-96.
2009: Sebastian Giebel; Jerzy Holowiecki; Malgorzata Krawczyk-Kulis; Krystyna Jagoda; Beata Stella-Holowiecka; Maria Sadus-Wojciechowska; Andrzej Hellmann; Anna Dmoszynska; Monika Paluszewska; Tadeusz Robak; Lech Konopka; Ilona Seferynska; Aleksander B Skotnicki; Slawomira Kyrcz-Krzemien
Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study.
Leukemia & lymphoma 2009;50(6):1050-3.
2009: Jan Peruga; Michal Plewka; Jaroslaw D Kasprzak; Tomasz Jezewski; Agnieszka Wierzbicka; Tadeusz Robak; Maria Krzemińska-Pakuła
Intracoronary administration of stem cells in patients with acute myocardial infarction - angiographic follow-up.
Kardiologia polska 2009;67(5):477-84.
2009: Anna Wolska; Ewa Lech-Maranda; Tadeusz Robak
Toll-like receptors and their role in hematologic malignancies.
Current molecular medicine 2009;9(3):324-35.
2009: Ewa Robak; M Kierstan; Barbara Cebula; Anna Krawczynska; Anna Sysa-Jedrzejowska; Agnieszka Wierzbowska; Piotr Smolewski; Tadeusz Robak
Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus.
Lupus 2009;18(4):332-41.
2009: Piotr Lipiec; Maria Krzemińska-Pakuła; Michal Plewka; Jacek Kuśmierek; Anna Płachcińska; Remigiusz Szumiński; Tadeusz Robak; Anna Korycka; Jaroslaw D Kasprzak
Impact of intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction on left ventricular perfusion and function: a 6-month follow-up gated 99mTc-MIBI single-photon emission computed tomography study.
European journal of nuclear medicine and molecular imaging 2009;36(4):587-93.
2009: Krzysztof Jamroziak; Zofia Szemraj; Olga Grzybowska-Izydorczyk; Janusz Szemraj; Magdalena Bieniasz; Barbara Cebula; Krzysztof Giannopoulos; Ewa Balcerczak; Dorota Jesionek-Kupnicka; Malgorzata Kowal; Aleksandra Kostyra; Malgorzata Calbecka; Ewa Wawrzyniak; Marek Mirowski; Radzislaw Kordek; Tadeusz Robak
CD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: evidence from two case-control studies in Polish Caucasians.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(3):945-53.
2009: Joanna Narbutt; Barbara Cebula; Aleksandra Lesiak; Anna Sysa-Jedrzejowska; Mary Norval; Tadeusz Robak; Piotr Smolewski
The effect of repeated exposures to low-dose UV radiation on the apoptosis of peripheral blood mononuclear cells.
Archives of dermatology 2009;145(2):133-8.
2009: Malgorzata Rogalinska; Pawel Goralski; Katarzyna Wozniak; Jolanta D Bednarek; Jerzy Z Blonski; Tadeusz Robak; Henryk Piekarski; Margaret Hanausek; Zbigniew Walaszek; Zofia M Kilianska
Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
Leukemia research 2009;33(2):308-14.
2009: Krzysztof Jamroziak; Ewa Balcerczak; Karolina Calka; Sylwester Piaskowski; Halina Urbanska-Rys; Aleksandra Salagacka; Marek Mirowski; Tadeusz Robak
Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma.
Leukemia research 2009;33(2):332-5.
2009: Tadeusz Robak; Agnieszka Wierzbowska
Current and emerging therapies for acute myeloid leukemia.
Clinical therapeutics 2009;31 Pt 2():2349-70.
2009: Tadeusz Robak; Krzysztof Jamroziak; Pawel Robak
Current and emerging treatments for chronic lymphocytic leukaemia.
Drugs 2009;69(17):2415-49.
2009: Tadeusz Robak
Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity.
Current medicinal chemistry 2009;16(18):2212-34.
2009: Tadeusz Robak; Anna Korycka; Ewa Lech-Maranda; Pawel Robak
Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.
Molecules (Basel, Switzerland) 2009;14(3):1183-226.
2009: Ewa Robak; Tadeusz Robak
Monoclonal antibodies in the treatment of systemic lupus erythematosus.
Current drug targets 2009;10(1):26-37.
2009: Joanna Gora-Tybor; Krzysztof Jamroziak; Anna Szmigielska-Kaplon; Anna Krawczynska; Ewa Lech-Maranda; Agnieszka Wierzbowska; Dorota Jesionek-Kupnicka; Jerzy Z Blonski; Tadeusz Robak
Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia.
Leukemia & lymphoma 2009;50(1):62-7.
2009: Anna Wolska; Ewa Lech-Marańda; Tadeusz Robak
Toll-like receptors and their role in carcinogenesis and anti-tumor treatment.
Cellular & molecular biology letters 2009;14(2):248-72.
2009: Tadeusz Robak; Jerzy Z Blonski; Ewa Wawrzyniak; Joanna Gora-Tybor; Aleksandra Palacz; Anna Dmoszynska; Lech Konopka; Krzysztof Warzocha; Krzysztof Jamroziak
Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
Cancer 2009;115(1):94-100.
2008: Joan Bladé; Pieter Sonneveld; Jesús F San Miguel; Heather J Sutherland; Roman Hajek; Arnon Nagler; Andrew Spencer; Tadeusz Robak; M Teresa Cibeira; Sen H Zhuang; Jean-Luc Harousseau; Robert Z Orlowski
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Clinical lymphoma & myeloma 2008;8(6):352-5.
2008: Pawel Robak; Piotr Smolewski; Tadeusz Robak
The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies.
Leukemia & lymphoma 2008;49(8):1452-62.
2008: Krzysztof Jamroziak; Tadeusz Robak
Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia?
Leukemia research 2008;32(8):1173-5.
2008: Ewa Kalinka-Warzocha; Jaroslaw Wajs; Ewa Lech-Maranda; Bernadetta Ceglarek; Jerzy Holowiecki; Irena Federowicz; Jan Walewski; Jaroslaw Czyz; Tadeusz Robak; Krzysztof Warzocha
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
Cancer 2008;113(2):367-75.
2008: Tadeusz Robak
Alemtuzumab for B-cell chronic lymphocytic leukemia.
Expert review of anticancer therapy 2008;8(7):1033-51.
2008: Anton Hagenbeek; Ole Gadeberg; Peter Johnson; Lars Møller Pedersen; Jan Walewski; Andrzej Hellmann; Brian K Link; Tadeusz Robak; Marek Wojtukiewicz; Michael Pfreundschuh; Michael Kneba; Andreas Engert; Pieter Sonneveld; Mimi Flensburg; Jørgen Petersen; Nedjad Losic; John Radford
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Blood 2008;111(12):5486-95.
2008: Anna Korycka; Ewa Lech-Marańda; Tadeusz Robak
Novel purine nucleoside analogues for hematological malignancies.
Recent patents on anti-cancer drug discovery 2008;3(2):123-36.
2008: Tadeusz Robak
Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders.
Current opinion in molecular therapeutics 2008;10(3):294-309.
2008: Elzbieta Smolewska; J Stańczyk; H Brózik; M Biernacka-Zielińska; Barbara Cebula; Tadeusz Robak; Piotr Smolewski
Distribution and clinical significance of blood dendritic cells in children with juvenile idiopathic arthritis.
Annals of the rheumatic diseases 2008;67(6):762-8.
2008: Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz Robak; Sen H Zhuang; Jean-Luc Harousseau; Robert Z Orlowski
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Cancer 2008;112(7):1529-37.
2008: Tadeusz Robak
Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.
Current cancer drug targets 2008;8(2):156-71.
2008: Tadeusz Robak
Emerging drugs for rarer chronic lymphoid leukemias.
Expert opinion on emerging drugs 2008;13(1):95-118.
2008: Agnieszka Wierzbowska; Tadeusz Robak; Agnieszka Pluta; Ewa Wawrzyniak; Barbara Cebula; Jerzy Hołowiecki; Sławomira Kyrcz-Krzemień; Sebastian Grosicki; Sebastian Giebel; Aleksander B Skotnicki; Beata Piatkowska-Jakubas; Kazimierz Kuliczkowski; Marek Kiełbiński; Krystyna Zawilska; Janusz Kłoczko; Agata Wrzesień-Kuś
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
European journal of haematology 2008;80(2):115-26.
2008: Agnieszka Wierzbowska; Tadeusz Robak; Anna Krawczyńska; Agnieszka Pluta; Agata Wrzesień-Kuś; Barbara Cebula; Ewa Robak; Piotr Smolewski
Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients.
Annals of hematology 2008;87(2):97-106.
2007: Ewa Robak; Lilianna Kulczycka; Anna Sysa-Jedrzejowska; Agnieszka Wierzbowska; Tadeusz Robak
Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus.
European cytokine network 2007;18(4):181-7.
2007: Tadeusz Robak
Recent progress in the management of chronic lymphocytic leukemia.
Cancer treatment reviews 2007;33(8):710-28.
2007: B Nasilowska-Adamska; P Rzepecki; J Manko; A Czyz; M Markiewicz; I Federowicz; Agnieszka Tomaszewska; Beata Piatkowska-Jakubas; Agata Wrzesien-Kus; Maria Bieniaszewska; D Duda; Richard Szydlo; Kazimierz Halaburda; A Szczepinski; A Lange; A Hellman; Tadeusz Robak; Aleksander B Skotnicki; Wieslaw Wiktor Jedrzejczak; Jan Walewski; Jerzy Holowiecki; Mieczyslaw Komarnicki; Anna Dmoszynska; Krzysztof Warzocha; Bozena Marianska
The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
Bone marrow transplantation 2007;40(10):983-8.
2007: Ewa Lech-Maranda; Ewa Robak; Anna Korycka; Tadeusz Robak
Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity.
Mini reviews in medicinal chemistry 2007;7(10):1062-9.
2007: Anna Korycka; Jerzy Z Błoński; Tadeusz Robak
Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Mini reviews in medicinal chemistry 2007;7(9):976-83.
2007: Ewa Robak; Dorota Jesionek-Kupnicka; Tadeusz Robak; A Holub; Ewa Wawrzyniak; Jacek Bartkowiak; Andrzej K Bednarek; M Constantinu; Halina Urbanska-Rys
Primary cutaneous marginal zone B-cell lymphoma in a patient with chronic lymphocytic leukaemia.
The British journal of dermatology 2007;157(3):591-5.
2007: Tadeusz Robak; Piotr Smolewski; Barbara Cebula; Olga Grzybowska-Izydorczyk; Jerzy Z Błoński
Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
European journal of haematology 2007;79(2):107-13.
2007: Tadeusz Robak; Ewa Lech-Maranda; Agnieszka Janus; Jerzy Z Blonski; Agnieszka Wierzbowska; Joanna Gora-Tybor
Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
Leukemia & lymphoma 2007;48(6):1092-101.
2007: Ewa Lech-Maranda; Przemyslaw Juszczynski; Anna Szmigielska-Kaplon; Krzysztof Jamroziak; Ewa Balcerczak; Tadeusz Robak
Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia?
Haematologica 2007;92(5):710-1.
2007: Anna Szmigielska-Kapłon; Dorota Jesionek-Kupnicka; Joanna Góra-Tybor; Jerzy Z Błonski; Ewa Lech-Marańda; Radzislaw Kordek; Marek Kasznicki; Tadeusz Robak
Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia.
Leukemia & lymphoma 2007;48(5):1042-4.
2007: Ewa Robak; Tadeusz Robak
Skin lesions in chronic lymphocytic leukemia.
Leukemia & lymphoma 2007;48(5):855-65.
2007: Tadeusz Robak; Krzysztof Jamroziak; Joanna Gora-Tybor; Jerzy Z Blonski; Marek Kasznicki; Jadwiga Dwilewicz - Trojaczek; Elzbieta Wiater; Andrzej Zdunczyk; Jacek Dybowicz; Anna Dmoszynska; Maria Wojtaszko; Barbara Zdziarska; Malgorzata Calbecka; Aleksandra Kostyra; Andrzej Hellmann; Krzysztof Lewandowski; Beata Stella-Holowiecka; Kazimierz Sulek; Krzysztof Gawronski; Aleksander B Skotnicki; Wieslaw Nowak; Krystyna Zawilska; Lucyna Molendowicz-Portala; Janusz Kloczko; Jaroslaw Sokolowski; Krzysztof Warzocha; Ilona Seferynska; Bernadetta Ceglarek; Lech Konopka
Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.
Blood 2007;109(9):3672-5.
2007: Tadeusz Robak; Pawel Robak
Current treatment options in prolymphocytic leukemia.
Medical science monitor : international medical journal of experimental and clinical research 2007;13(4):RA69-80.
2007: Marzena Wieczorkowska; Piotr Szajerski; Radosław Michalski; Jan Adamus; Andrzej Marciniak; Jerzy Gebicki; Ewa Ciesielska; Leszek Szmigiero; Ewa Lech-Marańda; Anna Szmigielska-Kapłon; Tadeusz Robak
Cytotoxic activity of the selected pyridinium salts against murine leukemia L1210.
Pharmacological reports : PR 2007;59(2):216-23.
2006: Pawel Robak; Anna Linke; Barbara Cebula; Tadeusz Robak; Piotr Smolewski
Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
Leukemia & lymphoma 2006;47(12):2625-34.
2006: Agnieszka Kobylinska; Jolanta Bednarek; Jerzy Z Blonski; Margaret Hanausek; Zbigniew Walaszek; Tadeusz Robak; Zofia M Kilianska
In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone.
Oncology reports 2006;16(6):1389-95.
2006: Piotr Smolewski; Markus Duechler; Anna Linke; Barbara Cebula; Olga Grzybowska-Izydorczyk; Medhat Shehata; Tadeusz Robak
Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.
Leukemia research 2006;30(12):1521-9.
2006: Krzysztof Jamroziak; Ewa Balcerczak; Barbara Cebula; Agnieszka Janus; Marek Mirowski; Tadeusz Robak
No influence of 3435C>T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells.
Therapeutic drug monitoring 2006;28(5):707-11.
2006: Tadeusz Robak; Piotr Smolewski; Barbara Cebula; Anna Szmigielska-Kaplon; Krzysztof Chojnowski; Jerzy Z Blonski
Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Cancer 2006;107(7):1542-50.
2006: Krzysztof Jamroziak; Ewa Balcerczak; Piotr Smolewski; Robert W Robey; Barbara Cebula; Mariusz Panczyk; Monika Kowalczyk; Anna Szmigielska-Kapłon; Marek Mirowski; Susan E Bates; Tadeusz Robak
MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia.
Pharmacological reports : PR 2006;58(5):720-8.
2006: Tadeusz Robak; Radzislaw Kordek; Halina Urbanska-Rys; Pawel Robak; Jacek Bartkowiak; Andrzej Bednarek; Cezary Chudobinski; Krzysztof Chojnowski
High activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvement.
Leukemia & lymphoma 2006;47(8):1667-9.
2006: Elzbieta Smolewska; Jerzy Stanczyk; Tadeusz Robak; Piotr Smolewski
Inhibited apoptosis of synovial fluid lymphocytes in children with juvenile idiopathic arthritis is associated with increased expression of myeloid cell leukemia 1 and XIAP proteins.
The Journal of rheumatology 2006;33(8):1684-90.
2006: Tadeusz Robak
Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
Cancer treatment reviews 2006;32(5):365-76.
2006: Tadeusz Robak; Jerzy Z Blonski; Joanna Gora-Tybor; Krzysztof Jamroziak; Jadwiga Dwilewicz - Trojaczek; Agnieszka Tomaszewska; Lech Konopka; Bernadetta Ceglarek; Anna Dmoszynska; Malgorzata Kowal; Janusz Kloczko; Beata Stella-Holowiecka; Kazimierz Sulek; Malgorzata Calbecka; Krystyna Zawilska; Kazimierz Kuliczkowski; Aleksander B Skotnicki; Krzysztof Warzocha; Marek Kasznicki
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2).
Blood 2006;108(2):473-9.
2006: A Wrzesień-Kuś; Tadeusz Robak; Agnieszka Pluta; M Zwolińska; Ewa Wawrzyniak; Agnieszka Wierzbowska; Aleksander B Skotnicki; Beata Jakubas; J Hołowiecki; Katarzyna Nowak; Kazimierz Kuliczkowski; Grzegorz Mazur; Olga Haus; A Dmoszyńska; Maria Adamczyk-Cioch; Wieslaw Wiktor Jedrzejczak; Monika Paluszewska; Lech Konopka; G Pałynyczko
Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
Annals of hematology 2006;85(6):366-73.
2006: Ewa Lech-Maranda; Anna Korycka; Tadeusz Robak
Pharmacological and clinical studies on purine nucleoside analogs--new anticancer agents.
Mini reviews in medicinal chemistry 2006;6(5):575-81.
2006: Tadeusz Robak
New agents in chronic lymphocytic leukemia.
Current treatment options in oncology 2006;7(3):200-12.
2006: Agnieszka Pluta; U Nyman; Bertrand Joseph; Tadeusz Robak; B Zhivotovsky; Piotr Smolewski
The role of p73 in hematological malignancies.
Leukemia 2006;20(5):757-66.
2006: Ewa Lech-Maranda; Jacques Bienvenu; Anne-Sophie Michallet; Roch Houot; Tadeusz Robak; Bertrand Coiffier; Gilles SALLES
Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma.
European cytokine network 2006;17(1):60-6.
2006: Ewa Robak; Anna Sysa-Jedrzejowska; Tadeusz Robak; Piotr Smolewski
Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms.
Clinical rheumatology 2006;25(2):225-33.
2006: Agnieszka Marczak; Aleksandra Kowalczyk; Agata Wrzesień-Kus; Tadeusz Robak; Zofia Jóźwiak
Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients.
Cell biology international 2006;30(2):127-32.
2006: Tadeusz Robak; Agnieszka Wierzbowska; Ewa Robak
Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders.
Reviews on recent clinical trials 2006;1(1):15-34.
2006: Tadeusz Robak; Anna Korycka; Ewa Robak
Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.
Recent patents on anti-cancer drug discovery 2006;1(1):23-38.
2006: Tadeusz Robak; Ewa Lech-Maranda; Anna Korycka; Ewa Robak
Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
Current medicinal chemistry 2006;13(26):3165-89.
2006: Olga Grzybowska-Izydorczyk; Joanna Góra-Tybor; Tadeusz Robak
[Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Postȩpy higieny i medycyny doświadczalnej (Online) 2006;60():490-7.
2006: Ewa Robak; Agnieszka Wierzbowska; Magdalena Chmiela; Lilianna Kulczycka; Anna Sysa-Jedrejowska; Tadeusz Robak
Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus.
Mediators of inflammation 2006;2006(1):17898.
2006: Joanna Narbutt; Aleksandra Lesiak; Anna Sysa-Jedrzejowska; Piotr Smolewski; Tadeusz Robak; Anna Zalewska
The number and distribution of blood dendritic cells in the epidermis and dermis of healthy human subjects.
Folia histochemica et cytobiologica / Polish Academy of Sciences, Polish Histochemical and Cytochemical Society 2006;44(1):61-3.
2005: Agnieszka Wierzbowska; Tadeusz Robak; Anna Krawczyńska; Agata Wrzesień-Kuś; Agnieszka Pluta; Barbara Cebula; Piotr Smolewski
Circulating endothelial cells in patients with acute myeloid leukemia.
European journal of haematology 2005;75(6):492-7.
2005: Krzysztof Jamroziak; Ewa Balcerczak; Barbara Cebula; Monika Kowalczyk; Mariusz Panczyk; Agnieszka Janus; Piotr Smolewski; Marek Mirowski; Tadeusz Robak
Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia.
Pharmacological reports : PR 2005;57(6):882-8.
2005: Jacek Treliński; Krzysztof Chojnowski; Magdalena Kurenko-Deptuch; Marek Kasznicki; Ewa Bernatowska; Tadeusz Robak
Successful treatment of refractory autoimmune thrombocytopenia with rituximab and cyclosporin A in a patient with chronic granulomatous disease.
Annals of hematology 2005;84(12):835-6.
2005: Tadeusz Robak; Jerzy Z Błoński; Marek Kasznicki; Joanna Góra-Tybor; Anna Dmoszyńska; Maria Wojtaszko; Aleksander B Skotnicki; Wieslaw Nowak; Andrzej Hellmann; Krzysztof Lewandowski; Barbara Zdziarska; Lech Konopka; Bernadetta Ceglarek; Jadwiga Dwilewicz - Trojaczek; Piotr Boguradzki; Kazimierz Kuliczkowski; Kazimierz Sułek; Krzysztof Warzocha
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).
Medical science monitor : international medical journal of experimental and clinical research 2005;11(10):PI71-9.
2005: Ewa Robak; Joanna Góra-Tybor; Radzislaw Kordek; Ewa Wawrzyniak; Jacek Bartkowiak; Andrzej K Bednarek; Maria Constantinou; B Kałuzewski; Tadeusz Robak
Richter syndrome first manifesting as cutaneous B-cell lymphoma clonally distinct from primary B-cell chronic lymphocytic leukaemia.
The British journal of dermatology 2005;153(4):833-7.
2005: Joanna Narbutt; Aleksandra Lesiak; Malgorzata Skibinska; Anna Wozniacka; Anna Sysa-Jedrzejowska; Anna Zalewska; Tadeusz Robak; Mary Norval; Piotr Smolewski
Lack of effect of repeated suberythemal ultraviolet-B exposures on human blood dendritic subtypes.
Photodermatology, photoimmunology & photomedicine 2005;21(5):249-53.
2005: Tadeusz Robak; Anna Korycka; Marek Kasznicki; Agata Wrzesien-Kus; Piotr Smolewski
Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications.
Current cancer drug targets 2005;5(6):421-44.
2005: A Wrzesień-Kuś; Tadeusz Robak; Agnieszka Wierzbowska; E Lech-Marańda; Agnieszka Pluta; Ewa Wawrzyniak; A Krawczyńska; Kazimierz Kuliczkowski; Grzegorz Mazur; M Kiebiński; A Dmoszyńska; Malgorzata Wach; Andrzej Hellmann; Wojciech Baran; J Hołowiecki; S Kyrcz-Krzemień; Sebastian Grosicki
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Annals of hematology 2005;84(9):557-64.
2005: Tadeusz Robak; A Szmigielska-Kapłon; J Z Błoński; Marek Kasznicki; Krzysztof Chojnowski
Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.
Chemotherapy 2005;51(5):247-51.
2005: Tadeusz Robak; Jerzy Z Blonski; Marek Kasznicki; Joanna Góra-Tybor; Anna Dmoszyñska; Aleksander Skotñicki
The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil.
Haematologica 2005;90(7):994-6.
2005: Marzenna Zielińska; Wlodzimierz Koniarek; Jan Henryk Goch; Barbara Cebula; Marzena Tybura; Tadeusz Robak; Piotr Smolewski
Circulating endothelial microparticles in patients with acute myocardial infarction.
Kardiologia polska 2005;62(6):531-42; discussion 543-4.
2005: Ewa Robak; Wojciech Biernat; Euzebiusz Krykowski; Arkadiusz Jeziorski; Tadeusz Robak
Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab.
Leukemia & lymphoma 2005;46(6):909-14.
2005: Markus Duechler; Anna Linke; Barbara Cebula; Medhat Shehata; Josef D Schwarzmeier; Tadeusz Robak; Piotr Smolewski
In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
European journal of haematology 2005;74(5):407-17.
2005: Tadeusz Robak
Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2005;32(1):33-44.
2005: Tadeusz Robak
The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Annals of hematology 2005;84(2):63-70.
2005: Ewa Kalinka; Przemyslaw Juszczynski; Grzegorz Woszczek; Maciej Borowiec; Tadeusz Robak; Marek Kowalski; Przemysław Biliński; Bertrand Coiffier; Gilles SALLES; Krzysztof Warzocha
[The role of HLA DRB1 genetic polymorphisms in non-Hodgkin's lymphomas].
Przegla̧d lekarski 2005;62(12):1422-6.
2005: Przemyslaw Juszczynski; Ewa Kalinka; Grzegorz Woszczek; Maciej Borowiec; Tadeusz Robak; Marek Kowalski; Przemysław Biliński; Bertrand Coiffiers; Gilles SALLES; Krzysztof Warzocha
[The role of genetic polymorphisms within tumor necrosis factor promoter gene in non-Hodgkin's lymphomas].
Przegla̧d lekarski 2005;62(12):1417-21.
2005: Tadeusz Robak
Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.
Drugs & aging 2005;22(12):983-1012.
2005: Agnieszka Janus; Tadeusz Robak; Piotr Smolewski
The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
Cellular & molecular biology letters 2005;10(3):479-98.
2005: Izabela Wojcik; Malgorzata Szybka; Ewa Golanska; Piotr Rieske; Jerzy Z Blonski; Tadeusz Robak; Jacek Bartkowiak
Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Neoplasma 2005;52(4):318-24.
2005: Joanna Gora-Tybor; Jerzy Z Blonski; Tadeusz Robak
Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia.
European cytokine network 2005;16(1):41-6.
2005: Tadeusz Robak
Alemtuzumab in the treatment of chronic lymphocytic leukemia.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2005;19(1):9-22.
2005: Małgorzata Rogalińska; Paweł Góralski; Agnieszka Kobylińska; Jerzy Z Błoński; Margaret Hanausek; Zbigniew Walaszek; Henryk Piekarski; Tadeusz Robak; Zofia M Kiliańska
Changes in leukemic cell nuclei revealed by differential scanning calorimetry.
Leukemia & lymphoma 2005;46(1):121-8.
2005: Piotr Smolewski; Anna Szmigielska-Kaplon; Barbara Cebula; Krzysztof Jamroziak; Malgorzata Rogalinska; Zofia M Kilianska; Tadeusz Robak
Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.
Leukemia & lymphoma 2005;46(1):87-100.
2004: Anna Korycka; Piotr Smolewski; Tadeusz Robak
The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.
European journal of haematology 2004;73(6):418-26.
2004: A Wrzesień-Kuś; Piotr Smolewski; A Sobczak-Pluta; Agnieszka Wierzbowska; Tadeusz Robak
The inhibitor of apoptosis protein family and its antagonists in acute leukemias.
Apoptosis : an international journal on programmed cell death 2004;9(6):705-15.
2004: Tadeusz Robak
Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia.
Hematology (Amsterdam, Netherlands) 2004;9(5-6):387-400.
2004: Joanna Narbutt; Malgorzata Skibinska; Aleksandra Lesiak; Anna Wozniacka; Anna Sysa-Jedrzejowska; Barbara Cebula; Tadeusz Robak; Piotr Smolewski
Exposure to low doses of solar-simulated radiation induces an increase in the myeloid subtype of blood dendritic cells.
Scandinavian journal of immunology 2004;60(4):429-35.
2004: Halina Urbańska-Ryś; Ewa Robak; Radzislaw Kordek; Jacek Bartkowiak; Piotr Rieske; Anna Woźniacka; Piotr Smolewski; Tadeusz Robak
Multiple myeloma in a patient with systemic lupus erythematosus, myasthenia gravis and non-familial diffuse palmoplantar keratoderma.
Leukemia & lymphoma 2004;45(9):1913-8.
2004: Jaroslaw Czyz; Rafal Dziadziuszko; W Knopinska-Postuszuy; Andrzej Hellmann; Lucja Kachel; Jerzy Holowiecki; J Gozdzik; Janusz Hansz; A Avigdor; A Nagler; M Osowiecki; Jan Walewski; Patrycja Mensah; Wojciech Jurczak; Aleksander B Skotnicki; M Sedzimirska; Andrzej Lange; Wieslaw Sawicki; Kazimierz Sulek; Malgorzata Wach; Anna Dmoszynska; A Kus; Tadeusz Robak; Krzysztof Warzocha
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(8):1222-30.
2004: Agnieszka Marczak; D Łubgan; Tadeusz Robak; Z Jóźwiak
Influence of 2-chlorodeoxyadenosine (cladribine) on human erythrocytes.
The international journal of biochemistry & cell biology 2004;36(8):1645-54.
2004: Ewa Robak; Piotr Smolewski; Anna Wozniacka; Anna Sysa-Jedrzejowska; Henryk Stepień; Tadeusz Robak
Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus.
European cytokine network 2004;15(3):222-30.
2004: Tadeusz Robak; Joanna Góra-Tybor; Krzysztof Tybor; Krzysztof Jamroziak; Pawel Robak; Radzislaw Kordek; Piotr Rieske; Agata Majos; Halina Urbańska-Ryś
Richter's syndrome in the brain first manifested as an ischaemic stroke.
Leukemia & lymphoma 2004;45(6):1261-7.
2004: Ewa Robak; Piotr Smolewski; A Woźniacka; Anna Sysa-Jedrzejowska; Tadeusz Robak
Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus.
Mediators of inflammation 2004;13(3):171-80.
2004: Jaroslaw Czyz; Richard Szydlo; Wanda Knopinska-Posluszny; Andrzej Hellmann; J Gozdzik; Janusz Hansz; P Smolewski; Tadeusz Robak; M Osowiecki; Jan Walewski; A Avigdor; A Nagler; T Zemelka; Marek Pawlicki; Z Sawicki; M Wojtukiewicz; Lucja Kachel; Jerzy Holowiecki; G Charlinski; Wieslaw Wiktor Jedrzejczak
Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy.
Bone marrow transplantation 2004;33(12):1225-9.
2004: Tadeusz Robak; Piotr Smolewski; Halina Urbanska-Rys; Joanna Gora-Tybor; Jerzy Z Blonski; Marek Kasznicki
Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
Leukemia & lymphoma 2004;45(5):937-44.
2004: Krzysztof Jamroziak; Wojciech Młynarski; Ewa Balcerczak; Magda Mistygacz; Joanna Trelinska; Marek Mirowski; Jerzy Bodalski; Tadeusz Robak
Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia.
European journal of haematology 2004;72(5):314-21.
2004: Jerzy Holowiecki; Sebastian Grosicki; Tadeusz Robak; Slawomira Kyrcz-Krzemien; Sebastian Giebel; Andrzej Hellmann; Aleksander B Skotnicki; Wieslaw Wiktor Jedrzejczak; Lech Konopka; Kazimierz Kuliczkowski; Barbara Zdziarska; Anna Dmoszynska; Bozena Marianska; Agnieszka Pluta; Krystyna Zawilska; Mieczyslaw Komarnicki; Janusz Kloczko; Kazimierz Sulek; Olga Haus; Beata Stella-Holowiecka; Wojciech Baran; Beata Jakubas; Monika Paluszewska; Agnieszka Wierzbowska; M Kielbinski; Krystyna Jagoda
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.
Leukemia 2004;18(5):989-97.
2004: Krzysztof Jamroziak; Tadeusz Robak
Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies.
Hematology (Amsterdam, Netherlands) 2004;9(2):91-105.
2004: Tadeusz Robak; A Szmigielska-Kapłon; A Wrzesień-Kuś; Agnieszka Wierzbowska; Aleksander B Skotnicki; Beata Piatkowska-Jakubas; Kazimierz Kuliczkowski; Grzegorz Mazur; A Zduńczyk; B Stella-Hołowiecka; J Hołowiecki; Jadwiga Dwilewicz - Trojaczek; K Madry; A Dmoszyńska; Maria Cioch
Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience.
Annals of hematology 2004;83(4):225-31.
2004: Agnieszka Kobylinska; Jerzy Z Blonski; Margaret Hanausek; Zbigniew Walaszek; Tadeusz Robak; Zofia M Kilianska
Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.
Oncology reports 2004;11(3):699-705.
2004: Tadeusz Robak
Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Leukemia & lymphoma 2004;45(2):205-19.
2004: Tadeusz Robak
Monoclonal antibodies in the treatment of autoimmune cytopenias.
European journal of haematology 2004;72(2):79-88.
2004: Tadeusz Robak; Jerzy Z Blonski; Joanna Gora-Tybor; Marek Kasznicki; Lech Konopka; Bernadetta Ceglarek; Mieczyslaw Komarnicki; K Lewandowski; Andrzej Hellmann; Krzysztof Lewandowski; A Moskwa; A Dmoszyńska; B Sokołowska; A Dwilewicz-Trojaczek; Agnieszka Tomaszewska; K Sułek; M Całbecka
Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine.
European journal of cancer (Oxford, England : 1990) 2004;40(3):383-9.
2004: Malgorzata Rogalińska; Jerzy Z Błoński; Margaret Hanausek; Zbigniew Walaszek; Tadeusz Robak; Zofia M Kiliańska
2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo.
Cancer detection and prevention 2004;28(6):433-42.
2004: Tadeusz Robak
Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches.
Drugs & aging 2004;21(12):779-91.
2004: Joanna Narbutt; Aleksandra Lesiak; Malgorzata Zak-Prelich; Anna Woźniacka; Anna Sysa-Jedrzejowska; Marzena Tybura; Tadeusz Robak; Piotr Smolewski
The distribution of peripheral blood dendritic cells assayed by a new panel of anti-BDCA monoclonal antibodies in healthy representatives of the polish population.
Cellular & molecular biology letters 2004;9(3):497-509.
2004: Krzysztof Jamroziak; Piotr Smolewski; Barbara Cebula; Anna Szmigielska-Kaplon; Zbigniew Darzynkiewicz; Tadeusz Robak
Relation of P-glycoprotein expression with spontaneous in vitro apoptosis in B-cell chronic lymphocytic leukemia.
Neoplasma 2004;51(3):181-7.
2003: Tadeusz Robak; Halina Urbańska-Ryś; Piotr Smolewski; Ewa Wawrzyniak; Anna Korycka; Radzislaw Kordek; Jacek Bartkowiak
Chronic myelomonocytic leukemia coexisting with B-cell chronic lymphocytic leukemia.
Leukemia & lymphoma 2003;44(11):2001-8.
2003: Ewa Robak; Anna Sysa-Jedrzejewska; Tadeusz Robak
Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
Mediators of inflammation 2003;12(5):293-8.
2003: Anna Korycka; Tadeusz Robak
The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Leukemia & lymphoma 2003;44(9):1549-55.
2003: A Wrzesień-Kuś; Tadeusz Robak; E Lech-Marańda; Agnieszka Wierzbowska; A Dmoszyńska; Malgorzata Kowal; J Hołowiecki; S Kyrcz-Krzemień; Sebastian Grosicki; Stanislaw Maj; Andrzej Hellmann; Aleksander B Skotnicki; Wieslaw Wiktor Jedrzejczak; Kazimierz Kuliczkowski
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
European journal of haematology 2003;71(3):155-62.
2003: Jerzy Hołowiecki; Sebastian Giebel; Jan Walewski; Małgorzata Krawczyk-Kuliś; Andrzej Hellmann; Aleksander B Skotnicki; Anna Dmoszyńska; Joanna Romejko; Jaroslaw Czyz; Wojciech Jurczak; Łucja Kachel; Jerzy Wojnar; Beata Stella-Hołowiecka; Maria Saduś-Wojciechowska; Kazimierz Sułek; Wieslaw Wiktor Jedrzejczak; Tadeusz Robak; Bozena Mariańska; Cezary Szczylik; Krzysztof Warzocha
[Autologous hematopoietic stem cell transplantation for the treatment of aggressive non-Hodgkin's lymphoma. The experience of Polish lymphoma research group].
Polskie Archiwum Medycyny Wewnętrznej 2003;110(2):863-8.
2003: Halina Urbańska-Ryś; Tadeusz Robak
High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Mediators of inflammation 2003;12(4):229-35.
2003: Tadeusz Robak; Halina Urbańska-Ryś; Joanna Góra-Tybor; Ewa Wawrzyniak; Anna Korycka; Jacek Bartkowiak; Radzislaw Kordek; Aaron Polliack
Coexistence of chronic lymphocytic leukemia and essential thrombocythemia.
Leukemia & lymphoma 2003;44(8):1425-31.
2003: Agnieszka Wierzbowska; Tadeusz Robak; Agata Wrzesień-Kuś; Anna Krawczyńska; Ewa Lech-Marańda; Halina Urbańska-Ryś
Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
European cytokine network 2003;14(3):149-53.
2003: Piotr Smolewski; Zbigniew Darzynkiewicz; Tadeusz Robak
Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment, and clinical implications.
Leukemia & lymphoma 2003;44(7):1089-104.
2003: Joanna Gora-Tybor; Jerzy Z Blonski; Tadeusz Robak
Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
Mediators of inflammation 2003;12(3):167-71.
2003: Tadeusz Robak; Anna Szmigielska-Kapłon; Piotr Smolewski; Ewa Wawrzyniak; Anna Korycka; Jacek Bartkowiak; Radzislaw Kordek
Hodgkin's type of Richter's syndrome in familial chronic lymphocytic leukemia treated with cladribine and cyclophosphamide.
Leukemia & lymphoma 2003;44(5):859-66.
2003: Tadeusz Robak
Purine nucleoside analogues in the treatment of myleoid leukemias.
Leukemia & lymphoma 2003;44(3):391-409.
2003: Agnieszka Marczak; Agata Wrzesień-Kuś; Euzebiusz Krykowski; Tadeusz Robak; Zofia Júźwiak
The interaction of daunorubicin and mitoxantrone with the red blood cells of acute myeloid leukemia patients.
Cellular & molecular biology letters 2003;8(4):885-90.
2003: Tadeusz Robak; A Szmigielska-Kapłon; H Urbańska-Ryś; Krzysztof Chojnowski; A Wrzesień-Kuś
Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Neoplasma 2003;50(3):172-5.
2003: Halina Urba ska-Rys; Agnieszka Wierzbowska; Tadeusz Robak
Circulating angiogenic cytokines in multiple myeloma and related disorders.
European cytokine network 2003;14(1):40-51.
2003: Anna Korycka; Tadeusz Robak
The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
Archivum immunologiae et therapiae experimentalis 2003;51(1):61-7.
2002: Tadeusz Robak; Halina Urbańska-Ryś; Piotr Jerzmanowski; Jacek Bartkowiak; Pawel P Liberski; Radzislaw Kordek
Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen--diagnostic and therapeutic dilemmas.
Leukemia & lymphoma 2002;43(12):2343-50.
2002: Przemyslaw Juszczynski; Grzegorz Woszczek; Maciej Borowiec; Marek Kowalski; Tadeusz Robak; Przemysław Biliński; Gilles SALLES; Krzysztof Warzocha
Comparison study for genotyping of a single-nucleotide polymorphism in the tumor necrosis factor promoter gene.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2002;11(4):228-33.
2002: Przemyslaw Juszczynski; Ewa Kalinka; Jacques Bienvenu; Grzegorz Woszczek; Maciej Borowiec; Tadeusz Robak; Marek Kowalski; Ewa Lech-Maranda; Lucile Baseggio; Bertrand Coiffier; Gilles SALLES; Krzysztof Warzocha
Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome.
Blood 2002;100(8):3037-40.
2002: Tadeusz Robak; Radzislaw Kordek; Ewa Robak; Jacek Bartkowiak; Wojciech Biernat; Pawel P Liberski; Jerzy Błoński
Langerhans cell histiocytosis in a patient with systemic lupus erythematosus: a clonal disease responding to treatment with cladribine, and cyclophosphamide.
Leukemia & lymphoma 2002;43(10):2041-6.
2002: Ewa Robak; Tadeusz Robak; Wojciech Biernat; Jacek Bartkowiak; Euzebiusz Krykowski
Successful treatment of leukaemia cutis with cladribine in a patient with B-cell chronic lymphocytic leukaemia.
The British journal of dermatology 2002;147(4):775-80.
2002: Krzysztof Jamroziak; Ewa Balcerczak; Wojciech Młynarski; Marek Mirowski; Tadeusz Robak
Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population.
Polish journal of pharmacology 2002;54(5):495-500.
2002: Anna Szmigielska-Kaplon; Piotr Smolewski; M Najder; Tadeusz Robak
Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
Annals of hematology 2002;81(9):508-13.
2002: Grazyna Józefowicz-Okonkwo; Anna Szmigielska-Kapłon; Tadeusz Robak
Cytotoxic effect of cyclosporin A alone and in combination with 2-chlorodeoxyadenosine against P388 murine leukemia in vivo.
Medical science monitor : international medical journal of experimental and clinical research 2002;8(9):BR373-7.
2002: Tadeusz Robak; Jerzy Z Boński; Marek Kasznicki; Joanna Góra-Tybor; Andrzej Hellmann; Lech Konopka; Anna Dmoszyńska; Jadwiga Dwilewicz - Trojaczek; Dariusz Wołowiec
Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
European journal of haematology 2002;69(1):27-36.
2002: Ewa Robak; Tadeusz Robak; Anna Wozniacka; Malgorzata Zak-Prelich; Anna Sysa-Jedrzejowska; Henryk Stepien
Proinflammatory interferon-gamma--inducing monokines (interleukin-12, interleukin-18, interleukin-15)--serum profile in patients with systemic lupus erythematosus.
European cytokine network 2002;13(3):364-8.
2002: Jaroslaw Czyz; Andrzej Hellmann; Rafal Dziadziuszko; Janusz Hansz; J Goździk; J Hołowiecki; B Stella-Hołowiecka; Ł Kachel; W Knopińska-Posłuszny; A Nagler; J Meder; Jan Walewski; E Lampka; K Sułek; Wieslaw Sawicki; Andrzej Lange; K Forgacz; Krzysztof Suchnicki; T Pacuszko; Aleksander B Skotnicki; Patrycja Mensah; Wojciech Jurczak; Kazimierz Kuliczkowski; Tomasz Wróbel; G Mazur; A Dmoszyńska; Malgorzata Wach; Tadeusz Robak; Krzysztof Warzocha
High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group.
Bone marrow transplantation 2002;30(1):29-34.
2002: Anna Szmigielska-Kaplon; Ewa Ciesielska; Leszek Szmigiero; Tadeusz Robak
Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro.
European journal of haematology 2002;68(6):370-5.
2002: Tadeusz Robak; Marek Kasznicki
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
Leukemia 2002;16(6):1015-27.
2002: Tadeusz Robak; Jacek Bartkowiak; Halina Urbańska-Rys; Anna Szmigielska-Kapłon; Boguslawa Strzelecka; Krzysztof Chojnowski
Acute lymphoblastic leukemia in adult first manifested as severe aplastic anemia--role of molecular analysis in correct diagnosis.
Leukemia & lymphoma 2002;43(5):1147-52.
2002: Tadeusz Robak; Halina Urbańska-Rys; Ewa Robak; Jacek Bartkowiak; Boguslawa Strzelecka; Wojciech Biernat; Radzislaw Kordek
Aggressive primary plasma cell leukemia with skin manifestations, trisomy 8 and molecular oligoclonal features.
Leukemia & lymphoma 2002;43(5):1067-73.
2002: Krzysztof Chojnowski; Jacek Treliński; Ewa Wawrzyniak; Tadeusz Robak
The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy--report of a prospective randomized study.
Leukemia & lymphoma 2002;43(5):1021-8.
2002: Ewa Kalinka; Tadeusz Robak; Agata Wrzesien-Kus; Euzebiusz Krykowski; Krzysztof Warzocha
Diagnostic and therapeutic quandaries in primary manifestation of Hodgkin's disease in the central nervous system.
Annals of hematology 2002;81(5):289-91.
2002: Tadeusz Robak
The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials.
Leukemia & lymphoma 2002;43(3):537-48.
2002: Jerzy Hołowiecki; Sebastian Giebel; Sławomira Krzemień; Małgorzata Krawczyk-Kuliś; Krystyna Jagoda; Malgorzata Kopera; Beata Hołowiecka; Sebastian Grosicki; Andrzej Hellmann; Anna Dmoszyńska; Monika Paluszewska; Tadeusz Robak; Lech Konopka; Stanislaw Maj; Jerzy Wojnar; Maria Wojciechowska; Aleksander B Skotnicki; Wojciech Baran; Maria Cioch
G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study.
Leukemia & lymphoma 2002;43(2):315-25.
2002: Tadeusz Robak; Agata Wrzesień-Kuś
The search for optimal treatment in relapsed and refractory acute myeloid leukemia.
Leukemia & lymphoma 2002;43(2):281-91.
2002: Agata Wrzesien-Kus; Tadeusz Robak; Krzysztof Jamroziak; Agnieszka Wierzbowska; Anna Dmoszynska; Maria Adamczyk-Cioch; Kazimierz Kuliczkowski; Grzegorz Mazur; Jerzy Holowiecki; Lech Konopka; Stanislaw Maj; Bozena Marianska; Krystyna Zawilska
The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Neoplasma 2002;49(6):405-11.
2002: Ewa Balcerczak; Jacek Bartkowiak; J Z Błoński; Tadeusz Robak; Marek Mirowski
Expression of gene encoding P65 oncofetal protein in acute and chronic leukemias.
Neoplasma 2002;49(5):295-9.
2002: Tadeusz Robak; Jerzy Z Błoński; Marek Kasznicki; Joanna Góra-Tybor; Jadwiga Dwilewicz - Trojaczek; Beata Stella-Hołowiecka; Dariusz Wołowiec
Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2002;3(5):244-50.
2002: Ewa Robak; A Woźniacka; Anna Sysa-Jedrzejowska; H Stepień; Tadeusz Robak
Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus.
Lupus 2002;11(6):348-55.
2002: Joanna Gora-Tybor; Jerzy Z Blonski; Tadeusz Robak
Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia.
Neoplasma 2002;49(3):145-8.
2002: Jacek Bartkowiak; D Kulczyck-Wojdala; Jerzy Z Blonski; Tadeusz Robak
Molecular diversity of gammadelta T cells in peripheral blood from patients with B-cell chronic lymphocytic leukaemia.
Neoplasma 2002;49(2):86-90.
2002: Przemyslaw Juszczynski; Wojciech Niewiarowski; Euzebiusz Krykowski; Tadeusz Robak; Krzysztof Warzocha
Expression of the multidrug resistance-associated protein (mrp) gene in chronic lymphocytic leukemia.
Leukemia & lymphoma 2002;43(1):153-8.
2001: Tadeusz Robak; H Urbańska-Ryś; Boguslawa Strzelecka; Euzebiusz Krykowski; Jacek Bartkowiak; J Z Bĺoński; Radzislaw Kordek; Krzysztof Warzocha
Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): an unusual variant of Richter's syndrome.
European journal of haematology 2001;67(5-6):322-7.
2001: Tadeusz Robak; J Z Błoński; Marek Kasznicki; I Góra-Tybor; Jadwiga Dwilewicz - Trojaczek; Piotr Boguradzki; Lech Konopka; Bernadetta Ceglarek; J Sułek; Kazimierz Kuliczkowski; D Wołowiec; B Stella-Hołowiecka; Aleksander B Skotnicki; Wieslaw Nowak; B Moskwa-Sroka; A Dmoszyńska; Malgorzata Calbecka
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
Leukemia 2001;15(10):1510-6.
2001: Tadeusz Robak; Marek Kasznicki; Jacek Bartkowiak; Radzislaw Kordek; Ewa Wawrzyniak; J Z Błonski
Richter's syndrome following cladribine therapy for chronic lymphocytic leukemia first manifested as pathologic fracture of the femur.
Leukemia & lymphoma 2001;42(4):789-96.
2001: Ewa Robak; Hanna Niewiadomska; Tadeusz Robak; Jacek Bartkowiak; J Z Błoński; A Woźniacka; Lech Pomorski; A Sysa-Jedrezejowska
Lymphocyctes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity.
Mediators of inflammation 2001;10(4):179-89.
2001: Ewa Robak; A Woźniacka; Anna Sysa-Jedrzejowska; H Stepień; Tadeusz Robak
Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
European cytokine network 2001;12(3):445-52.
2001: Tadeusz Robak; Ewa Robak; Jacek Bartkowiak; J Z Błoński; Hanna Niewiadomska; Ewa Wawrzyniak
Low-grade non-Hodgkin's lymphoma in a patient with systemic lupus erythematosus.
Leukemia & lymphoma 2001;41(5-6):659-67.
2001: Z M Kiliańska ; J Chruściel; H Niewiadomska; J Błoński; M Rogalińska; A Błaszczyk; Tadeusz Robak
Altered expression of nuclear non-histone protein (p44/46) in different stages of B-chronic lymphocytic leukemia.
Leukemia & lymphoma 2001;41(5-6):635-42.
2001: Tadeusz Robak; J Z Błoński ; Marek Kasznicki
Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?
Leukemia & lymphoma 2001;41(5-6):545-57.
2001: Tadeusz Robak; Joanna Góra-Tybor; E Lech-Marańda; J Z Błoński; Marek Kasznicki
Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
European journal of haematology 2001;66(3):188-94.
2001: Tadeusz Robak; Marek Kasznicki; J Z Bloński; A Dmoszyńska; Aleksander B Skotnicki
Pure red cell aplasia in patients with chronic lymphocytic leukaemia treated with cladribine.
British journal of haematology 2001;112(4):1083-5.
2001: Tadeusz Robak
Cladribine in the treatment of chronic lymphocytic leukemia.
Leukemia & lymphoma 2001;40(5-6):551-64.
2001: Jan Walewski; Ewa Kraszewska; O Mioduszewska; J Romejko-Jarosińska; Andrzej Hellmann; Jaroslaw Czyz; J Hołowiecki; Malgorzata Kopera; Sebastian Grosicki; Mieczyslaw Komarnicki; L Rumianowski; K Kuliczkowski; Tomasz Wróbel; Jadwiga Dwilewicz - Trojaczek; Tadeusz Robak; Krzysztof Warzocha; J Załuski; E Wójcik; A Dmoszyńska; Adam Walter-Croneck
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.
Medical oncology (Northwood, London, England) 2001;18(2):141-8.
2001: M Rogalińska; J Błoński; Tadeusz Robak; Z M Kiliańska
Enzyme-linked immunosorbent assay in screening of leukemia-associated nuclear proteins.
Cellular & molecular biology letters 2001;6(3):637-48.
2001: Tadeusz Robak; Joanna Góra-Tybor
Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.
Neoplasma 2001;48(3):203-7.
2001: Z M Kiliańska; P Szymczyk; Wanda M Krajewska; J Jakubik; J Błoński; J Berner; Tadeusz Robak
Nuclear non-histone protein p36 associated with colorectal tumours.
Cytobios 2001;106 Suppl 1():35-42.
2001: M Rogalińska; J Błoński; Tadeusz Robak; Z M Kiliańska
Two-dimensional gel electrophoresis of nuclear proteins of different stages of B-chronic lymphocytic leukaemia.
Cytobios 2001;106(412):101-12.
2001: Ewa Robak; Tadeusz Robak; Joanna Góra-Tybor; Krzysztof Chojnowski; Boguslawa Strzelecka; Elzbieta Waszczykowska; Anna Sysa-Jedrzejowska
Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF.
Journal of medicine 2001;32(1-2):31-9.
2000: E Lech-Marańda; Anna Korycka; Tadeusz Robak
Influence of gemcitabine (2',2'-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro.
European journal of haematology 2000;65(5):317-21.
2000: Tadeusz Robak; J Z Bloński; Marek Kasznicki; M Blasińska-Morawiec; Euzebiusz Krykowski; A Dmoszyńska; H Mrugala-Spiewak; Aleksander B Skotnicki; Wieslaw Nowak; Lech Konopka; Bernadetta Ceglarek; Stanislaw Maj; Jadwiga Dwilewicz - Trojaczek; Andrzej Hellmann; I Urasiński; Barbara Zdziarska; Sabina Kotlarek-Haus; Stanislaw Potoczek; P Grieb
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.
Blood 2000;96(8):2723-9.
2000: H Urbańska-Ryś; A Wiersbowska; H Stepień; Tadeusz Robak
Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
European cytokine network 2000;11(3):443-51.
2000: Tadeusz Robak; A Wrzesień-Kuś; E Lech-Marańda; Malgorzata Kowal; A Dmoszyńska
Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Leukemia & lymphoma 2000;39(1-2):121-9.
2000: Piotr Smolewski; Hanna Niewiadomska; E Los; Tadeusz Robak
Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells; clinical and pathological implications in patients with Hodgkin's disease.
International journal of oncology 2000;17(3):603-9.
2000: Ewa Lech-Maranda; Anna Korycka; Tadeusz Robak
The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro.
Haematologica 2000;85(6):588-94.
2000: Piotr Smolewski; Tadeusz Robak; Euzebiusz Krykowski; M Blasiñska-Morawiec; Hanna Niewiadomska; Anna Pluzanska; E Chmielowska; O Zambrano
Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):1150-60.
2000: Tadeusz Robak; J Z Bloński; Marek Kasznicki; Lech Konopka; Bernadetta Ceglarek; A Dmoszyńska; Maria Soroka-Wojtaszko; Aleksander B Skotnicki; Wieslaw Nowak; Jadwiga Dwilewicz - Trojaczek; Agnieszka Tomaszewska; Andrzej Hellmann; Krzysztof Lewandowski; Kazimierz Kuliczkowski; Stanislaw Potoczek; Barbara Zdziarska; Janusz Hansz; R Kroll; Mieczyslaw Komarnicki; Jerzy Holowiecki; P Grieb
Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients.
British journal of haematology 2000;108(2):357-68.
2000: Tadeusz Robak; Joanna Góra-Tybor; Krzysztof Chojnowski
Cladribine as monotherapy or combined with dexamethasone and idarubicin or mitoxantrone in previously treated patients with low-grade lymphoid malignancies.
Haematologica 2000;85(2):215-6.
2000: Slawomir Mucha; K Zylińska; Hanna Pisarek; Jan Komorowski; Tadeusz Robak; Anna Korycka; H Stepień
Pituitary-adrenocortical responses to the chronic administration of granulocyte colony-stimulating factor in rats.
Journal of neuroimmunology 2000;102(1):73-8.
2000: Joanna Gora-Tybor; E Lech-Miranda; Jerzy Z Blonski; Tadeusz Robak
2-chlorodeoxyadenosine (2-CdA) does not change the expression of Fas antigen on chronic lymphocytic leukaemia cells.
Advances in experimental medicine and biology 2000;486():307-10.
2000: A Korycka; Tadeusz Robak
The influence of amifostine used alone or in combination with 2-chlorodeoxyadenosine on normal and chronic myelogenous leukemia granulocyte-macrophage progenitor cells in vitro.
Archivum immunologiae et therapiae experimentalis 2000;48(4):293-9.
2000: Tadeusz Robak; A Szmigielska
Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388.
Neoplasma 2000;47(3):168-71.
1999: K Zylińska; Slawomir Mucha; Jan Komorowski; Anna Korycka; Hanna Pisarek; Tadeusz Robak; H Stepień
Influence of granulocyte-macrophage colony stimulating factor on pituitary-adrenal axis (PAA) in rats in vivo.
Pituitary 1999;2(3):211-6.
1999: Ewa Robak; A Woźniacka; A Sysa-J&ecedil;drzejowska; Wojciech Biernat; Tadeusz Robak
Disseminated superficial actinic porokeratosis in a patient with systemic lupus erythematosus.
The British journal of dermatology 1999;141(4):759-61.
1999: Tadeusz Robak; Marek Kasznicki; Boguslawa Strzelecka; Jacek Bartkowiak; M Debiec-Rychter
Atypical chronic myelogenous leukemia following immunosuppressive therapy for severe aplastic anemia.
Leukemia & lymphoma 1999;35(1-2):193-9.
1999: J Chruściel; J Błonski; P Szymczyk; Tadeusz Robak; Z M Kiliańska
A novel B-CLL specific nuclear protein (p44/46).
Leukemia research 1999;23(9):833-41.
1999: Andrzej Hellmann; Krzysztof Lewandowski; Jan M Zaucha; Maria Bieniaszewska; K Hałaburda; Tadeusz Robak
Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia.
European journal of haematology 1999;63(1):35-41.
1999: Tadeusz Robak; M Błasińska-Morawiec; J Z Błoński; A Dmoszyńska
2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia.
Leukemia & lymphoma 1999;34(1-2):151-7.
1999: Agnieszka Wierzbowska; H Urbańska-Ryś; Tadeusz Robak
Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
British journal of haematology 1999;105(2):412-9.
1999: Tadeusz Robak; J Z Błoński; H Urbańska-Ryś; M Błasińska-Morawiec; Aleksander B Skotnicki
2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger.
Leukemia 1999;13(4):518-23.
1999: Ewa Robak; J Z Błoński; Jacek Bartkowiak; Hanna Niewiadomska; Anna Sysa-Jedrzejowska; Tadeusz Robak
Circulating TCR gammadelta cells in the patients with systemic lupus erythematosus.
Mediators of inflammation 1999;8(6):305-12.
1999: Tadeusz Robak; Agnieszka Wierzbowska; M Błasińska-Morawiec; Anna Korycka; J Z Błoński
Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Mediators of inflammation 1999;8(6):277-86.
1999: Piotr Smolewski; Hanna Niewiadomska; Euzebiusz Krykowski; Tadeusz Robak
Expression of p21 and MDM-2 proteins on tumor cells in responding and non-responding patients with Hodgkin's disease.
Neoplasma 1999;46(4):212-8.
1999: E Marañda; A Szmigielska; Tadeusz Robak
Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388.
Cancer investigation 1999;17(2):95-101.
1999: Tadeusz Robak; Joanna Gora-Tybor; H Urbańska-Ryś; Euzebiusz Krykowski
Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 1999;32(3-4):359-63.
1999: Tadeusz Robak; M Błasińska-Morawiec; J Błoński; Andrzej Hellmann; K Hałaburda; Lech Konopka; Sabina Kotlarek-Haus; Stanislaw Potoczek; Janusz Hansz; A Dmoszyńska; I Urasiński; Barbara Zdziarska; Jadwiga Dwilewicz - Trojaczek; J Hołowiecki; Aleksander B Skotnicki
2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
European journal of haematology 1999;62(1):49-56.
1998: Tadeusz Robak; A Gladalska; H Stepień
The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
European cytokine network 1998;9(2):145-54.
1998: Tadeusz Robak; A Gladalska; H Stepień; Ewa Robak
Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
Mediators of inflammation 1998;7(5):347-53.
1998: Ewa Robak; A Sysa-Jedrzejewska; B Dziankowska; D Torzecka; Krzysztof Chojnowski; Tadeusz Robak
Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity.
Archivum immunologiae et therapiae experimentalis 1998;46(6):375-80.
1998: Tadeusz Robak
Interferon alpha in the treatment of chronic myelogenous leukemia.
Archivum immunologiae et therapiae experimentalis 1998;46(6):347-53.
1998: Piotr Smolewski; Hanna Niewiadomska; J Z Błonski; Tadeusz Robak; Euzebiusz Krykowski
Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: prognostic significance in Hodgkin's disease.
Neoplasma 1998;45(3):140-7.
1998: E Marańda; Tadeusz Robak
Interactions of 2',2'-diflurodeoxycytidine (gemcitabine) with tumor necrosis factor alpha or its mutein VI in murine leukemias L1210 and P388.
Archivum immunologiae et therapiae experimentalis 1998;46(2):113-9.
1997: Tadeusz Robak; M Błasińska-Morawiec; J Z Błoński; Euzebiusz Krykowski; Mieczyslaw Komarnicki; E Trepińska; M Kaźmierczuk; Janusz Hansz; A Dmoszyńska; J Roliński; Lech Konopka; Aleksander B Skotnicki; Wieslaw Nowak; Sabina Kotlarek-Haus; Barbara Zdziarska; I Urasiński
The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia.
European journal of cancer (Oxford, England : 1990) 1997;33(14):2347-51.
1997: Tadeusz Robak; M Błasińska-Morawiec; Euzebiusz Krykowski; Andrzej Hellmann; Krzysztof Lewandowski; A Dmoszyńska; Maria Adamczyk-Cioch; M Kazimierczak; E Trepińska; M Dwilewicz-Trojaczek; Z Kuratowska; Aleksander B Skotnicki; Wieslaw Nowak; Barbara Zdziarska; I Urasiński
2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases.
European journal of haematology 1997;59(4):216-20.
1997: Anna Korycka; Tadeusz Robak
The influence of recombinant human tumor necrosis factor alpha and its muteins used alone or in combination with 2-chlorodeoxyadenosine on normal and leukemic hematopoiesis in vitro.
Leukemia research 1997;21(9):857-65.
1997: Ewa Robak; Anna Sysa-Jedrzejowska; H Stepień; Tadeusz Robak
Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus.
European cytokine network 1997;8(3):281-6.
1997: M Blasińska-Morawiec; Tadeusz Robak; Euzebiusz Krykowski; Andrzej Hellmann; H Urbańska-Ryś
Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine--a report of three cases.
Leukemia & lymphoma 1997;25(3-4):381-5.
1997: Tadeusz Robak; M Błasińska-Morawiec; Euzebiusz Krykowski; Andrzej Hellmann; Lech Konopka
Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine).
European journal of haematology 1997;58(2):109-13.
1997: Tadeusz Robak; Anna Sysa-Jedrzejowska; Ewa Robak; J Dabkowski; M Blasinska-Morawiec
2-chlorodeoxyadenosine (cladribine) induced allergic cutaneous reactions with eosinophilia in a patient with B-cell chronic lymphocytic leukemia.
Journal of medicine 1997;28(3-4):199-209.
1997: Krzysztof Warzocha; K Fabianowska-Majewska; J Bloński; Euzebiusz Krykowski; Tadeusz Robak
2-Chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukaemia.
European journal of cancer (Oxford, England : 1990) 1997;33(1):170-3.
1996: Tadeusz Robak; M Błasinka-Morawiec; Euzebiusz Krykowski; M Kasznicki; A Płuzanska; Piotr Potemski; Andrzej Hellmann; Jan M Zaucha; Krzysztof Lewandowski; Anna Dmoszynska; Janusz Hansz; Mieczyslaw Komarnicki; Lech Konopka; T Durzynski; B Ceglarek; A Sikorska; Sabina Kotlarek-Haus; G Mazur; Ignacy Urasinski; Barbara Zdziarska; S Maj; I Kopec; Aleksander B Skotnicki; Jadwiga Dwilewicz - Trojaczek; Pawel Grieb
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
Leukemia & lymphoma 1996;22(5-6):509-14.
1996: Tadeusz Robak; M Błasińska-Morawiec; Euzebiusz Krykowski; Janusz Hansz; Mieczyslaw Komarnicki; M Kazimierczak; Lech Konopka; S Maj; Andrzej Hellmann; Jan M Zaucha; L Urasiński; Barbara Zdziarska; Sabina Kotlarek-Haus; Lidia Usnarska-Zubkiewicz; Z Kuratowska; Jadwiga Dwilewicz - Trojaczek; J Hołowiecki; M Krawczyk-Kulis; Pawel Grieb
2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.
Leukemia & lymphoma 1996;22(1-2):107-11.
1996: Krzysztof Warzocha; E Krykowksi; J Góra-Tybor; A Fronczak; Tadeusz Robak
Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma.
Leukemia & lymphoma 1996;21(3-4):343-6.
1996: Tadeusz Robak; Anna Korycka
The comparison of 2-chlorodeoxyadenosine (2-Cd A) in combination with interferon alpha (IFN alpha) or interferon gamma (IFN gamma) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts in (CFU-L) in vitro cultures.
Leukemia & lymphoma 1996;21(1-2):161-8.
1996: Ewa Robak; Anna Sysa-Jedrzejowska; Tadeusz Robak; H Stepień; A Woźniacka; E Waszczykowsk
Tumour necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6) and their soluble receptors (sTNF-alpha-Rp55 and slL-6R) serum levels in systemic lupus erythematodes.
Mediators of inflammation 1996;5(6):435-41.
1996: Jan Komorowski; K Zylińska; Slawomir Mucha; Tadeusz Robak; A Wrzesien-Kus; H Stepień
Effect of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor on prolactin and adrenocorticotropic hormone secretion in rats: dose- and time-response in vivo studies.
Cytobios 1996;86(346):147-53.
1996: A Korycka; Tadeusz Robak
Interaction of 2-chlorodeoxyadenosine in combination either with interferons or recombinant human tumor necrosis factor alpha on myeloid progenitor cells in vitro.
Archivum immunologiae et therapiae experimentalis 1996;44(4):259-64.
1996: J Góra-Tybor; Euzebiusz Krykowski; Tadeusz Robak
Treatment of drug-induced agranulocytosis with colony stimulating factors (G-CSF or GM-CSF).
Archivum immunologiae et therapiae experimentalis 1996;44(4):255-8.
1996: Piotr Smolewski; K Chojnowski; J Filutowicz; Euzebiusz Krykowski; Tadeusz Robak; M Dubla-Berner; W Pruszczyński
[Thrombotic thrombocytopenic purpura successfully treated with plasma exchange].
Przegla̧d lekarski 1996;53(8):636-8.
1996: Ewa Robak; Anna Sysa-Jedrzejowska; Tadeusz Robak
[Cytokines in systemic lupus erythematosus].
Przegla̧d lekarski 1996;53(8):623-6.
1996: Tadeusz Robak
Cytokines in the treatment of hematological disorders: recent progress and perspectives.
Archivum immunologiae et therapiae experimentalis 1996;44(1):5-9.
1995: K Zylińska; Jan Komorowski; Tadeusz Robak; Slawomir Mucha; H Stepień
Effect of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor on melatonin secretion in rats in vivo and in vitro studies.
Journal of neuroimmunology 1995;56(2):187-90.
1995: Euzebiusz Krykowski; Krzysztof Warzocha; Tadeusz Robak
2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
Archivum immunologiae et therapiae experimentalis 1995;43(5-6):317-21.
1995: Tadeusz Robak; Ewa Robak; Anna Sysa-Jedrzejowska
[Hematologic problems in systemic lupus erythematosus].
Acta haematologica Polonica 1995;26(2):145-51.
1994: Tadeusz Robak; Anna Korycka; J Góra-Tybor
The interaction of 2-chlorodeoxyadenosine (2-CDA) and interferon alpha (IFN-alpha) on normal and myeloid leukemia hematopoiesis in vitro.
Leukemia research 1994;18(4):275-81.
1994: Tadeusz Robak
[The role of interferons in treating hematopoietic system neoplasms].
Polski tygodnik lekarski (Warsaw, Poland : 1960) 1994;49(12-13):307-10.
1994: Tadeusz Robak; Euzebiusz Krykowski; Krzysztof Warzocha
Treatment of chemotherapy-induced or idiopathic bone marrow aplasia with granulocyte colony-stimulating factor (G-CSF).
Archivum immunologiae et therapiae experimentalis 1994;42(5-6):433-8.
1994: Tadeusz Robak
[Biological properties and clinical applications of interferon gamma (IFN-gamma)].
Acta haematologica Polonica 1994;25(1):19-29.
1994: Tadeusz Robak
[Clinical applications of erythropoietin].
Acta haematologica Polonica 1994;25(2 Suppl 1):112-23.
1994: Krzysztof Warzocha; Tadeusz Robak; Euzebiusz Krykowski
[Thrombocytopenia during pregnancy].
Przegla̧d lekarski 1994;51(3):152-7.
1994: A Krawczyńska; Tadeusz Robak
[Acute basophilic leukemia].
Acta haematologica Polonica 1994;25(4):323-7.
1994: Tadeusz Robak; J Treliński; A Hołub
[Anagrelide--new antiplatelet drug].
Acta haematologica Polonica 1994;25(4):309-15.
1994: Krzysztof Warzocha; Krystyna Fabianowska-Majewska; Tadeusz Robak
[Adenosine deaminase (ADA), 5'-nucleotidase (5'N) and purine nucleoside phosphorylase (PNP) in lympho- and myeloproliferative disorders].
Przegla̧d lekarski 1994;51(12):531-5.
1994: J Góra-Tybor; Tadeusz Robak
The influence of 2-chlorodeoxyadenosine (2-CdA) alone and in combination with cyclophosphamide or methotrexate on normal and leukemic hematopoiesis.
Advances in experimental medicine and biology 1994;370():129-30.
1994: Tadeusz Robak
[Stem cell factor].
Acta haematologica Polonica 1994;25(3):205-14.
1994: J Góra-Tybor; Tadeusz Robak; Krzysztof Warzocha; P Grieb
Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
Archivum immunologiae et therapiae experimentalis 1994;42(1):39-42.
1994: Tadeusz Robak; Euzebiusz Krykowski; M Błasińska-Morawiec; H Urbańska-Ryś
Treatment of patients with hairy cell leukemia with 2-chloro-2'-deoxyadenosine (2-CdA).
Archivum immunologiae et therapiae experimentalis 1994;42(1):25-9.
1993: Tadeusz Robak; T Olszańska-Skorek; Euzebiusz Krykowski; M Kasznicki; J Wilczyński
[Therapeutic problems during pregnancy and delivery in two women with aplastic anemia].
Acta haematologica Polonica 1993;24(2):183-9.
1993: J Góra-Tybor; Tadeusz Robak
Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Acta haematologica Polonica 1993;24(2):177-82.
1993: J Góra-Tybor; Tadeusz Robak
The influence of 2-chlorodeoxyadenosine alone and in combination with cyclophosphamide or methotrexate on normal hematopoiesis in mice.
Acta haematologica Polonica 1993;24(3):281-7.
1993: Tadeusz Robak; Euzebiusz Krykowski; Krzysztof Warzocha; P Kończalik
Application of hematopoietic growth factors (G-CSF and GM-CSF) in the treatment of chemotherapy-induced or idiopathic bone marrow failure.
Acta haematologica Polonica 1993;24(3):253-62.
1992: Krzysztof Warzocha; Tadeusz Robak
Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
Acta haematologica Polonica 1992;23(1):55-62.
1992: Tadeusz Robak
[Use of interferon in the treatment of chronic myeloproliferative disorders].
Acta haematologica Polonica 1992;23(2 Suppl 1):30-7.
1992: H Urbańska-Ryś; Tadeusz Robak; Euzebiusz Krykowski
[Secondary leukemia].
Acta haematologica Polonica 1992;23(2):71-7.
1992: Tadeusz Robak; M Błasińska-Morawiec; Euzebiusz Krykowski
Transient eosinophilia in a patient with hairy-cell leukaemia treated with 2-chlorodeoxyadenosine.
Acta haematologica Polonica 1992;23(4):285-90.
1992: Tadeusz Robak; Anna Korycka; J Góra-Tybor; A Piotrowska-Wrzesień; Euzebiusz Krykowski
The influence of recombinant human tumor necrosis factor (rh-TNF alpha) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic leukaemic blasts (CFU-L) in cultures in vitro.
Archivum immunologiae et therapiae experimentalis 1992;40(5-6):339-43.
1992: Tadeusz Robak; Euzebiusz Krykowski; Krzysztof Warzocha
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
Archivum immunologiae et therapiae experimentalis 1992;40(5-6):331-7.
1991: Tadeusz Robak; Euzebiusz Krykowski; L Brodowski; A Zawadzka-Bandura; H Urbańska-Ryś; M Błasińska-Morawiec; W Matusewicz
[Results of treating acute myeloblastic leukemia in patients over 60 years of age].
Polski tygodnik lekarski (Warsaw, Poland : 1960) 1991;46(48-49):931-4.
1991: M Błasińska-Morawiec; A Płuzańska; Euzebiusz Krykowski; Tadeusz Robak; I Mrówka
[Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone)].
Polskie Archiwum Medycyny Wewnętrznej 1991;86(4):274-80.
1990: Tadeusz Robak; Euzebiusz Krykowski; A Płuzańska; T Olszańska-Skorek; M Kowalczyński; H Urbańska-Ryś
[Efficacy of lomustine, teniposide, doxorubicin, bleomycin and prednisone (LTABP) or adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) in the treatment of malignant lymphogranulomatosis resistant to MOPP].
Polski tygodnik lekarski (Warsaw, Poland : 1960) 1990;45(21-22):426-9.
1989: J Drzewoski; Euzebiusz Krykowski; Tadeusz Robak; P Jerzmanowski; J Kusowska; H Koźbiał
[Ventricular fibrillation in a patient with myelodysplastic syndrome treated with small doses of cytarabine].
Kardiologia polska 1989;32(4):225-8.
1989: Tadeusz Robak
Antigenic characteristics of circulating granulocyte-macrophage progenitors (CFU-GM) in idiopathic myelofibrosis and polycythaemia vera defined by monoclonal antibodies.
Archivum immunologiae et therapiae experimentalis 1989;37(1-2):17-28.
1988: Tadeusz Robak; Euzebiusz Krykowski; W Matusewicz; L Brodowski; A Hołub; J Drzewoski
[Results of treating acute myeloid leukemia resistant to conventional chemotherapy with moderately large doses of cytarabine and etoposide].
Polski tygodnik lekarski (Warsaw, Poland : 1960) 1988;43(47):1508-11.
1988: Tadeusz Robak; Euzebiusz Krykowski; W Matusewicz; T Olszańska-Skorek; H Urbańska-Ryś
[Large doses of cytarabine, etoposide and methotrexate (CEM protocol) in the treatment of lymphoblastic leukemia in adults, resistant to conventional treatment, and of recurrences].
Polski tygodnik lekarski (Warsaw, Poland : 1960) 1988;43(11):351-4.
1988: H Urbańska-Ryś; Tadeusz Robak; Euzebiusz Krykowski
[Biology and clinical aspects of primary myelodysplastic syndromes].
Polski tygodnik lekarski (Warsaw, Poland : 1960) 1988;43(7):225-9.
1988: Tadeusz Robak
Antigenic characteristics of erythropoietin dependent and independent erythroid progenitors (BFU-E and CFU-E) in polycythaemia vera and idiopathic myelofibrosis defined by monoclonal antibodies.
Archivum immunologiae et therapiae experimentalis 1988;36(6):733-47.
1988: Tadeusz Robak
Application of monoclonal antibodies in the antigenic characteristics of normal myeloid progenitor cells and clonogenic blasts in acute myeloid leukaemia.
Archivum immunologiae et therapiae experimentalis 1988;36(1):71-84.
1988: Tadeusz Robak
Antigenic phenotype of chronic granulocytic leukaemia progenitor cells in chronic phase and in blastic transformation characterized by means of monoclonal antibodies.
Archivum immunologiae et therapiae experimentalis 1988;36(4):471-85.
1987: Tadeusz Robak
Expression of myeloid differentiation antigens on normal and chronic granulocytic leukemia erythroid progenitor cells identified by monoclonal antibodies.
Archivum immunologiae et therapiae experimentalis 1987;35(4):519-29.
1987: Euzebiusz Krykowski; E Polkowska-Kulesza; Tadeusz Robak; W Matusewicz; H Urbańska-Rys; A Hołub
Analysis of prognostic factors in acute leukemias in adults.
Haematology and blood transfusion 1987;30():369-72.
1986: Tadeusz Robak; Euzebiusz Krykowski; T Olszańska-Skorek; H Urbańska-Ryś; M Dmochowska; K Chojnowski
[Use of lomustine, teniposide, procarbazine and prednisone (LTPP) in the treatment of terminal-state Hodgkin's disease].
Polski tygodnik lekarski (Warsaw, Poland : 1960) 1986;41(7):199-202.
1983: Tadeusz Robak; Euzebiusz Krykowski; A Płuzańska; T Olszańska-Skorek; H Urbańska-Ryś; E Polkowska-Kulesza; M Błasińska-Morawiec; A Mazurowa
[Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
Polski tygodnik lekarski (Warsaw, Poland : 1960) 1983;38(16):481-4.
1983: W Matusewicz; J Drzewoski; Tadeusz Robak; Euzebiusz Krykowski
[Myocardial infarct in a patient with Hodgkin's disease treated with cyclic polychemotherapy].
Kardiologia polska 1983;26(7):591-4.
1982: Tadeusz Robak; A Płuzańska; M Dmochowska; Euzebiusz Krykowski; W Oliskiewicz; S Fajndt; J Maciejczyk; W Jabłkowski; A Mazurowa
[Effect of splenectomy on hematological tolerance and the results of chemotherapy in Hodgkin's disease].
Acta haematologica Polonica 1982;13(1-2):5-11.
1981: D Apel; M Bielawiec; A Bodzenta; M Brandowska; S Dabrowski; M Gepner-Woźniewska; M Gamski; A Hellman; J Hołowiecki; J Japa; D Jarczak; A Janowska-Wieczorek; Beata Kiersnowska-Rogowska; J Kłoczko; Sabina Kotlarek-Haus; J Kowalewski; Euzebiusz Krykowski; H Lukjan; Stanislaw Maj; M Matera; A Mazurowa; M Myśliwiec; S Pawelski; Tadeusz Robak; J Sowińska; I Urasiński; K Wysocki
[Treatment of acute leukemias in adults. IV. Treatment results on 375 patients at 9 hematology centers].
Acta haematologica Polonica 1981;12(3-4):155-9.
1980: A Mazurowa; Euzebiusz Krykowski; Tadeusz Robak; A Płuzańska; E Polkowska-Kulesza; T Olszańska-Skorek
[Results of complex treatment of adults with myeloblastic leukemia].
Polski tygodnik lekarski (Warsaw, Poland : 1960) 1980;35(31):1187-9.
1980: A Płuzańska; E Polkowska-Kulesza; Tadeusz Robak; J Kuźmicka; A Mazurowa; A Szadowska; L Woźniak
[Surface markers of the lymphoid cells in non-Hodgkin's lymphoma].
Acta haematologica Polonica 1980;11(1):31-9.
1980: A Płuzańska; E Gawor; Tadeusz Robak; E Polkowska-Kulesza; Euzebiusz Krykowski; M Dmochowska; J Kuźmicka; A Mazurowa
[Prognostic value of peripheral blood T-lymphocyte count in lymphocytic leukemia].
Acta haematologica Polonica 1980;11(1):25-30.